Literature DB >> 15023815

Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function.

David A Bennett1, Julie A Schneider, Robert S Wilson, Julia L Bienias, Steven E Arnold.   

Abstract

OBJECTIVE: To test the hypothesis that the association of amyloid load with clinical Alzheimer disease (AD) and cognitive impairment is mediated through neurofibrillary tangles.
DESIGN: Longitudinal clinicopathologic cohort study. PARTICIPANTS AND
SETTING: Forty-four individuals with clinically diagnosed AD and 53 without dementia who participated in the Religious Orders Study underwent a uniform structured clinical evaluation for AD and cognitive testing about 8 months prior to death, and brain autopsy at death.
METHODS: The percent area occupied by amyloid-beta and the density of neurofibrillary tangles were quantified from 6 brain regions and averaged to yield summary measures of amyloid load and neurofibrillary tangles. Multivariate regression analyses were used to simultaneously examine the effects of amyloid load and neurofibrillary tangles on clinically diagnosed AD and level of cognition. MAIN OUTCOME MEASURES: Clinically diagnosed AD and level of global cognitive function proximate to death.
RESULTS: In separate logistic regression analyses, each 1% increase in amyloid load was associated with about a 50% increase in the odds of clinical AD (P =.002), and each neurofibrillary tangle was associated with a greater than 20% increase in the odds of clinical AD (P<.001). When a term for tangles was added to the regression model with amyloid, the association of amyloid load with clinical disease was reduced by more than 60% and was no longer significant, whereas the association of tangles with clinical disease was essentially unchanged. Similar results were found in analyses of global cognitive function.
CONCLUSION: These findings are consistent with a sequence of pathologic events whereby the effect of amyloid deposition on clinical disease is mediated by neurofibrillary tangles.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023815     DOI: 10.1001/archneur.61.3.378

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  215 in total

1.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Clifford R Jack; Marilyn S Albert; David S Knopman; Guy M McKhann; Reisa A Sperling; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 2.  Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect?

Authors:  Dennis W Dickson
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 3.  Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology.

Authors:  Daniel J Glass; Steven E Arnold
Journal:  Alzheimers Dement       Date:  2011-12-03       Impact factor: 21.566

4.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

5.  Neurodegenerative basis of age-related cognitive decline.

Authors:  R S Wilson; S E Leurgans; P A Boyle; J A Schneider; D A Bennett
Journal:  Neurology       Date:  2010-09-15       Impact factor: 9.910

6.  Association of anxiety and depression with microtubule-associated protein 2- and synaptopodin-immunolabeled dendrite and spine densities in hippocampal CA3 of older humans.

Authors:  Ainie Soetanto; Robert S Wilson; Konrad Talbot; Ashley Un; Julie A Schneider; Mark Sobiesk; Jeremiah Kelly; Sue Leurgans; David A Bennett; Steven E Arnold
Journal:  Arch Gen Psychiatry       Date:  2010-05

Review 7.  Selected findings from the Religious Orders Study and Rush Memory and Aging Project.

Authors:  David A Bennett; Robert S Wilson; Zoe Arvanitakis; Patricia A Boyle; Leyla de Toledo-Morrell; Julie A Schneider
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

8.  Residual decline in cognition after adjustment for common neuropathologic conditions.

Authors:  Lei Yu; Patricia A Boyle; Eisuke Segawa; Sue Leurgans; Julie A Schneider; Robert S Wilson; David A Bennett
Journal:  Neuropsychology       Date:  2014-12-15       Impact factor: 3.295

9.  Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people.

Authors:  D A Bennett; J A Schneider; R S Wilson; J L Bienias; E Berry-Kravis; S E Arnold
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

10.  BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.

Authors:  Yen Ying Lim; Jason Hassenstab; Carlos Cruchaga; Alison Goate; Anne M Fagan; Tammie L S Benzinger; Paul Maruff; Peter J Snyder; Colin L Masters; Ricardo Allegri; Jasmeer Chhatwal; Martin R Farlow; Neill R Graff-Radford; Christoph Laske; Johannes Levin; Eric McDade; John M Ringman; Martin Rossor; Stephen Salloway; Peter R Schofield; David M Holtzman; John C Morris; Randall J Bateman
Journal:  Brain       Date:  2016-08-12       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.